AI-assisted, human-published

08/13/2024 /Technology

Pelage Pharmaceuticals Initiates Phase 2a Trial for PP405, Raises $14 Million in Series A-1 Funding

Pelage Pharmaceuticals has commenced the Phase 2a clinical trial for PP405, a new topical small molecule aimed at treating androgenetic alopecia. Additionally, the company secured $14 million in Series A-1 funding led by GV.

 

AI-assisted, human-published

Latest headlines







join us

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here

©2023 VentureCapital.com